 |
|
|
| |
Safety, Tolerability, Pharmacokinetics (PK) and Antiviral Activity of EDP-494, a Potent Pan-Genotypic Cyclophilin (Cyp) Inhibitor for Chronic Hepatitis C Infection (CHC), in Healthy Subjects (HS) and in CHC Genotype 1 and 3 Patients: Preliminary Results
|
| |
| |
Reported by Jules Levin
AASLD 2016 Nov 11-15 Boston, MA
Edward J. Gane2,1, Lijuan Jiang3, Christian Schwabe2, Lisa Morelli3, Kai Lin3, Yat Sun Or3, Nathalie Adda3
1New Zealand Liver Transplant Unit, Auckland City Hospital, Auckland, New Zealand; 2Clinical Research Unit, Auckland Clinical Studies,, Auckland, New Zealand; 3Enanta Pharmaceuticals, Inc., Watertown, MA
|
| |
|
|
|
|
|
